216 related articles for article (PubMed ID: 27669017)
1. High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors.
Becker DL; Chit A; DiazGranados CA; Maschio M; Yau E; Drummond M
Hum Vaccin Immunother; 2016 Dec; 12(12):3036-3042. PubMed ID: 27669017
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.
Chit A; Becker DL; DiazGranados CA; Maschio M; Yau E; Drummond M
Lancet Infect Dis; 2015 Dec; 15(12):1459-66. PubMed ID: 26362172
[TBL] [Abstract][Full Text] [Related]
3. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines.
DiazGranados CA; Robertson CA; Talbot HK; Landolfi V; Dunning AJ; Greenberg DP
Vaccine; 2015 Sep; 33(38):4988-93. PubMed ID: 26212007
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty.
DiazGranados CA; Dunning AJ; Robertson CA; Talbot HK; Landolfi V; Greenberg DP
Vaccine; 2015 Aug; 33(36):4565-71. PubMed ID: 26187260
[TBL] [Abstract][Full Text] [Related]
5. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
Chit A; Roiz J; Briquet B; Greenberg DP
Vaccine; 2015 Jan; 33(5):734-41. PubMed ID: 25444791
[TBL] [Abstract][Full Text] [Related]
6. Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults.
DiazGranados CA; Dunning AJ; Robertson CA; Talbot HK; Landolfi V; Greenberg DP
Clin Infect Dis; 2016 May; 62(9):1092-1099. PubMed ID: 26908801
[TBL] [Abstract][Full Text] [Related]
7. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: a cluster randomized trial.
Kwong JC; Pereira JA; Quach S; Pellizzari R; Dusome E; Russell ML; Hamid JS; Feinberg Y; Winter AL; Gubbay JB; Sirtonski B; Moher D; Sider D; Finkelstein M; Loeb M;
Vaccine; 2015 Jan; 33(4):535-41. PubMed ID: 25488331
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of high-dose versus standard-dose influenza vaccine in older adults.
DiazGranados CA; Dunning AJ; Kimmel M; Kirby D; Treanor J; Collins A; Pollak R; Christoff J; Earl J; Landolfi V; Martin E; Gurunathan S; Nathan R; Greenberg DP; Tornieporth NG; Decker MD; Talbot HK
N Engl J Med; 2014 Aug; 371(7):635-45. PubMed ID: 25119609
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Wateska A; France GS; Zimmerman RK
Vaccine; 2017 Oct; 35(42):5708-5713. PubMed ID: 28890196
[TBL] [Abstract][Full Text] [Related]
10. Relative and Absolute Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults-United States, 2015-2017.
Doyle JD; Beacham L; Martin ET; Talbot HK; Monto A; Gaglani M; Middleton DB; Silveira FP; Zimmerman RK; Alyanak E; Smith ER; Flannery BL; Rolfes M; Ferdinands JM
Clin Infect Dis; 2021 Mar; 72(6):995-1003. PubMed ID: 32067049
[TBL] [Abstract][Full Text] [Related]
11. Fluzone® High-Dose Influenza Vaccine.
Robertson CA; DiazGranados CA; Decker MD; Chit A; Mercer M; Greenberg DP
Expert Rev Vaccines; 2016 Dec; 15(12):1495-1505. PubMed ID: 27813430
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review.
Colrat F; Thommes E; Largeron N; Alvarez FP
Vaccine; 2021 Mar; 39 Suppl 1():A42-A50. PubMed ID: 33518466
[TBL] [Abstract][Full Text] [Related]
13. Cost Effectiveness of Influenza Vaccine for U.S. Children: Live Attenuated and Inactivated Influenza Vaccine.
Shim E; Brown ST; DePasse J; Nowalk MP; Raviotta JM; Smith KJ; Zimmerman RK
Am J Prev Med; 2016 Sep; 51(3):309-17. PubMed ID: 27079638
[TBL] [Abstract][Full Text] [Related]
14. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) cluster randomized trial: Pilot results from a household surveillance study to assess direct and indirect protection from influenza vaccination.
Kwong JC; Pereira JA; Quach S; Pellizzari R; Dusome E; Russell ML; Hamid JS; Feinberg Y; Winter AL; Gubbay JB; Sirtonski B; Moher D; Sider D; Finkelstein M; Loeb M;
Vaccine; 2015 Sep; 33(38):4910-5. PubMed ID: 26232348
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.
Izurieta HS; Thadani N; Shay DK; Lu Y; Maurer A; Foppa IM; Franks R; Pratt D; Forshee RA; MaCurdy T; Worrall C; Howery AE; Kelman J
Lancet Infect Dis; 2015 Mar; 15(3):293-300. PubMed ID: 25672568
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans.
Richardson DM; Medvedeva EL; Roberts CB; Linkin DR;
Clin Infect Dis; 2015 Jul; 61(2):171-6. PubMed ID: 25829001
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of inactivated influenza vaccination in children with medical risk conditions in the Netherlands.
Naber SK; Bruijning-Verhagen PCJL; de Hoog MLA; van Giessen A
Vaccine; 2020 Apr; 38(17):3387-3396. PubMed ID: 32115297
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
[TBL] [Abstract][Full Text] [Related]
20. Cost Benefit of High-Dose vs Standard-Dose Influenza Vaccine in a Long-Term Care Population During an A/H1N1-Predominant Influenza Season.
Shireman TI; Ogarek J; Gozalo P; Zhang T; Mor V; Davidson HE; Han L; Taljaard M; Gravenstein S
J Am Med Dir Assoc; 2019 Jul; 20(7):874-878. PubMed ID: 30777631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
